Erin Wright
Stock Analyst at Morgan Stanley
(2.00)
# 186
Out of 4,786 analysts
219
Total ratings
66.67%
Success rate
0.78%
Average return
Main Sectors:
Stocks Rated by Erin Wright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVST Envista Holdings | Maintains: Equal-Weight | $20 → $19 | $17.26 | +10.08% | 8 | Mar 6, 2025 | |
| ELAN Elanco Animal Health | Maintains: Equal-Weight | $14 → $13 | $10.50 | +23.81% | 11 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $243 → $238 | $164.65 | +44.55% | 7 | Feb 14, 2025 | |
| HUM Humana | Maintains: Equal-Weight | $301 → $285 | $264.60 | +7.71% | 3 | Feb 12, 2025 | |
| ALGN Align Technology | Maintains: Overweight | $280 → $272 | $158.86 | +71.22% | 21 | Feb 6, 2025 | |
| CI The Cigna Group | Maintains: Overweight | $403 → $379 | $329.00 | +15.20% | 4 | Jan 31, 2025 | |
| CAH Cardinal Health | Maintains: Overweight | $136 → $142 | $137.77 | +3.07% | 9 | Jan 31, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $559 → $550 | $419.95 | +30.97% | 12 | Jan 29, 2025 | |
| PDCO Patterson Companies | Maintains: Equal-Weight | $27 → $31 | $31.24 | +0.35% | 9 | Dec 17, 2024 | |
| MCK McKesson | Maintains: Overweight | $612 → $642 | $672.99 | -4.60% | 5 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $25 | $21.36 | +17.04% | 21 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $23 | $14.94 | +53.95% | 12 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $20 | $18.09 | +10.56% | 2 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $145 → $172 | $169.20 | +1.65% | 5 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $643 → $551 | $434.96 | +26.68% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $9 → $7 | $11.17 | -37.33% | 7 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $6.5 → $3.5 | $4.19 | -16.47% | 11 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $69 → $65 | $68.49 | -5.10% | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $67.75 | +47.60% | 4 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $587 | $523.75 | +12.08% | 3 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $300 | $232.74 | +28.90% | 4 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $42 | $16.21 | +159.10% | 5 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $282 → $288 | $205.00 | +40.49% | 6 | Jun 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $342 → $352 | $150.52 | +133.86% | 4 | May 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $44 | $2.21 | +1,890.95% | 2 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $178 → $181 | $304.69 | -40.60% | 8 | Mar 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $17 | $97.60 | -82.58% | 6 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $121 | $32.51 | +272.19% | 7 | Jan 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $556 → $580 | $497.60 | +16.56% | 4 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $9.90 | +253.54% | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $181 → $205 | $174.99 | +17.15% | 2 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $11 | $16.90 | -34.91% | 6 | May 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $175 → $157 | $176.30 | -10.95% | 1 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $38 | $19.28 | +97.10% | 1 | May 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $31 → $17 | $9.03 | +88.26% | 1 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $300 → $308 | $446.71 | -31.05% | 1 | Oct 25, 2017 | |
Envista Holdings
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $20 → $19
Current: $17.26
Upside: +10.08%
Elanco Animal Health
Feb 26, 2025
Maintains: Equal-Weight
Price Target: $14 → $13
Current: $10.50
Upside: +23.81%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $243 → $238
Current: $164.65
Upside: +44.55%
Humana
Feb 12, 2025
Maintains: Equal-Weight
Price Target: $301 → $285
Current: $264.60
Upside: +7.71%
Align Technology
Feb 6, 2025
Maintains: Overweight
Price Target: $280 → $272
Current: $158.86
Upside: +71.22%
The Cigna Group
Jan 31, 2025
Maintains: Overweight
Price Target: $403 → $379
Current: $329.00
Upside: +15.20%
Cardinal Health
Jan 31, 2025
Maintains: Overweight
Price Target: $136 → $142
Current: $137.77
Upside: +3.07%
IDEXX Laboratories
Jan 29, 2025
Maintains: Overweight
Price Target: $559 → $550
Current: $419.95
Upside: +30.97%
Patterson Companies
Dec 17, 2024
Maintains: Equal-Weight
Price Target: $27 → $31
Current: $31.24
Upside: +0.35%
McKesson
Dec 17, 2024
Maintains: Overweight
Price Target: $612 → $642
Current: $672.99
Upside: -4.60%
Dec 17, 2024
Maintains: Equal-Weight
Price Target: $20 → $25
Current: $21.36
Upside: +17.04%
Dec 17, 2024
Maintains: Overweight
Price Target: $30 → $23
Current: $14.94
Upside: +53.95%
Dec 17, 2024
Maintains: Overweight
Price Target: $19 → $20
Current: $18.09
Upside: +10.56%
Dec 17, 2024
Upgrades: Overweight
Price Target: $145 → $172
Current: $169.20
Upside: +1.65%
Oct 23, 2024
Maintains: Overweight
Price Target: $643 → $551
Current: $434.96
Upside: +26.68%
Oct 11, 2024
Maintains: Underweight
Price Target: $9 → $7
Current: $11.17
Upside: -37.33%
Jun 12, 2024
Maintains: Underweight
Price Target: $6.5 → $3.5
Current: $4.19
Upside: -16.47%
Nov 14, 2023
Maintains: Underweight
Price Target: $69 → $65
Current: $68.49
Upside: -5.10%
Nov 2, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $67.75
Upside: +47.60%
Jul 14, 2023
Reiterates: Overweight
Price Target: $587
Current: $523.75
Upside: +12.08%
Aug 22, 2022
Assumes: Overweight
Price Target: $300
Current: $232.74
Upside: +28.90%
Jul 30, 2021
Maintains: Outperform
Price Target: $39 → $42
Current: $16.21
Upside: +159.10%
Jun 18, 2021
Maintains: Outperform
Price Target: $282 → $288
Current: $205.00
Upside: +40.49%
May 28, 2021
Maintains: Neutral
Price Target: $342 → $352
Current: $150.52
Upside: +133.86%
May 11, 2021
Maintains: Outperform
Price Target: $42 → $44
Current: $2.21
Upside: +1,890.95%
Mar 17, 2021
Maintains: Outperform
Price Target: $178 → $181
Current: $304.69
Upside: -40.60%
Feb 26, 2021
Maintains: Neutral
Price Target: $14 → $17
Current: $97.60
Upside: -82.58%
Jan 13, 2021
Maintains: Outperform
Price Target: $104 → $121
Current: $32.51
Upside: +272.19%
Jan 12, 2021
Maintains: Outperform
Price Target: $556 → $580
Current: $497.60
Upside: +16.56%
Jan 5, 2021
Initiates: Neutral
Price Target: $35
Current: $9.90
Upside: +253.54%
Jul 23, 2020
Maintains: Outperform
Price Target: $181 → $205
Current: $174.99
Upside: +17.15%
May 5, 2020
Maintains: Neutral
Price Target: $12 → $11
Current: $16.90
Upside: -34.91%
Apr 2, 2020
Maintains: Outperform
Price Target: $175 → $157
Current: $176.30
Upside: -10.95%
May 9, 2018
Maintains: Outperform
Price Target: $42 → $38
Current: $19.28
Upside: +97.10%
Nov 20, 2017
Maintains: Underperform
Price Target: $31 → $17
Current: $9.03
Upside: +88.26%
Oct 25, 2017
Maintains: Neutral
Price Target: $300 → $308
Current: $446.71
Upside: -31.05%